NCT06676644 Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines
| NCT ID | NCT06676644 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Influenza Vaccines |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-11-21 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare the immunogenicity, cellular immune response, and safety between adjuvanted (aIIV4) and non-adjuvanted (IIV4) seasonal influenza vaccines in the Taiwanese elderly population with chronic medical conditions.
Eligibility Criteria
Inclusion Criteria: * Adults aged 65 years or above * Presence of at least 1 chronic medical condition associated with increased risk of complicated influenza, including hypertension, chronic obstructive pulmonary disease (group A, B, E), asthma, congestive heart failure (ACC/AHA stage A, B, C, D), coronary arterial disease, diabetes mellitus, chronic liver disease (Child-Pugh score A, B, C) or chronic kidney disease (stage 1\~4), neuromuscular disorders, hematological or solid organ malignancies, recipient of hematopoietic stem cell transplantation or solid organ transplantation. Exclusion Criteria: * Contraindications to influenza vaccination including history of severe adverse event after vaccination, such as anaphylaxis or Guillain-Barré Syndrome, or a severe bleeding tendency * Prior receipt of influenza vaccination during the current flu season. * Determination by the Principal Investigator (PI) that the participant is ineligible for enrollment based on clinical assessment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06676644 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Influenza Vaccines. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06676644 currently recruiting?
Yes, NCT06676644 is actively recruiting participants. Contact the research team at wangjt1124@ntuh.gov.tw for enrollment information.
Where is the NCT06676644 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06676644 clinical trial?
NCT06676644 is sponsored by National Taiwan University Hospital. The trial plans to enroll 200 participants.